LifeSpan Sells GPCR Portfolio to MBL, Plans to Continue Antibody Line | GenomeWeb

NEW YORK, Feb. 21 (GenomeWeb News) - LifeSpan BioSciences has sold "most of its existing catalog" of antibodies to Medical and Biological Laboratories International, LifeSpan confirmed today.


The Massachusetts-based subsidiary of Nagoya, Japan-based MBL bought 921 antibodies to about 400 different protein targets, including 800 GPCR antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.